564 Results (Page 20 of 23)
Japan Markets Research Reports
Japan Depression Therapeutics Market Analysis
The Japan depression therapeutics market is expected to witness growth from $628 Mn in 2022 to $978 Mn in 2030 with a CAGR of 5.7% for the forecasted year 2022-2030. The growth in research and development initiatives in Japan and the increasing prevalence of depression among the Japanese population are driving the growth of the market. The Japan depression therapeutics market is segmented by drug type, therapies, indication, and by end users. Kyowa Hakko Kirin, Mitsubishi Tanabe Pharma, and AstraZeneca are the major players in the Japan depression therapeutics market.
Japan Liver Cancer Therapeutics Market Analysis
By 2030, it is anticipated that the Japan liver cancer therapeutics market will reach a value of $689.2 Mn from $182.12 Mn in 2022, growing at a CAGR of 18.1% during 2022-30. The liver cancer therapeutics market in Japan is dominated by a few domestic pharmaceutical companies such as Chugai Pharmaceutical, Taiho Pharmaceutical, and Eisai. The liver cancer therapeutics market in Japan is segmented into different types of cancer and different therapy type. Some of the major factors affecting this market are the growing prevalence of liver cancer and the high cost and side effects related to certain liver cancer therapies.
Japan Lung Cancer Therapeutics Market Analysis
By 2030, it is anticipated that the Japan Lung Cancer Therapeutics Market will reach a value of $3.5 Bn from $1.8 Bn in 2022, growing at a CAGR of 8.6% during 2022-2030. The Lung Cancer Therapeutics Market in Japan is dominated by a few domestic pharmaceutical companies such as Chugai Pharmaceutical, Taiho Pharmaceutical, and Ono Pharmaceutical. The Lung Cancer Therapeutics Market in Japan is segmented into different types of cancer and different therapy type. Some of the major factors affecting the Japanese lung cancer therapeutics market are the prevalence of unhealthy lifestyles, demand for targeted therapies and the presence of highly efficient drugs.
Japan Oncology Therapeutics Market Analysis
By 2030, it is anticipated that the Japan Oncology Therapeutics Market will reach a value of $22.3 Bn from $11.2 Bn in 2022, growing at a CAGR of 8.9% during 2022-2030. The Oncology Therapeutics Market in Japan is dominated by a few domestic pharmaceutical companies such as Takeda Pharmaceutical, Daiichi Sankyo, and Astellas Pharma. The Oncology Therapeutics Market in Japan is segmented into different types of cancer and different therapy type. The major risk factors associated with cancer are diet, alcohol, tobacco, air pollution, and physical inactivity. The demand for Japan Oncology Therapeutics is increasing on account of the rise in initiatives taken by the Government of the country.
Japan Cardiac Surgery Instruments Market Analysis
The Japan Cardiac Surgery Instruments Market is expected to witness growth from $129 Mn in 2022 to $223 Mn in 2030 with a CAGR of 7.10% for the forecasted year 2022-2030. Japan's population is ageing at one of the fastest rates in the world, which is anticipated to increase demand for instruments used in cardiac surgery since older people are more likely to develop cardiac diseases. The market is segmented by type, application and by end user. Some key players in this market include Terumo Corporation, Fukuda, LivaNova, B. Braun, Medline Industries, KLS Martin, and STILLE.
Japan Artificial Intelligence (AI) in Healthcare Market Analysis
Japan's Artificial Intelligence (AI) in the healthcare market is projected to grow from $0.43 Bn in 2022 to $8.72 Bn by 2030, registering a CAGR of 45.72% during the forecast period of 2022-30. The market will be driven by the country's aging population and it's technologically advanced infrastructure. The market is segmented by healthcare components & by healthcare applications. Some of the major players include GE Healthcare, Hitachi, Ltd & A-Traction.
Japan Biomaterials in Healthcare Market Analysis
The Japan Biomaterials Healthcare Market is expected to witness growth from $9.71 Bn in 2022 to $27.12 Bn in 2030 with a CAGR of 13.70% for the forecasted year 2022-2030. In Japan, the prevalence of illnesses like gingivitis, tooth decay, oral cancer, halitosis, and dental caries is increasing, which is fueling demand for biomaterials and boosting the country's biomaterial healthcare market. The market is segmented by type and by application. Some key players in this market include: Terumo, Asahi Kasei Corporation, Menicon, BASF SE, Johnson and Johnson, Medtronic and Evonik Industries.
Japan Anti Aging Therapeutics Market Analysis
Japan anti-aging therapeutics market is projected to grow from $38 Mn in 2022 to $132 Mn in 2030 with a CAGR of 17.03% for the year 2022-2030. Japan has the fastest-growing geriatric population which results in increased demand for anti-aging treatments. Further, in Japan, there is the presence of highly advanced technology which results in the expansion of the market. The Japan anti-aging therapeutics market is segmented by product, treatment, target group, type of aging, type of molecules, mechanism of action, ingredient, and by distribution channel. Modulus Discovery, Noile-Immune Biotech, and NeuroTrack are some of the top players in the market.
Japan 3D Printing Medical Devices Market Analysis
Japan 3D Printing Medical Device Market is expected to witness growth from $185 Mn in 2022 to $639 Mn in 2030 with a CAGR of 16.80% for the forecasted year 2022-2030. The Japan market for 3D-printed medical devices is expanding as a result of the ongoing creation of new 3D printing technologies and materials. Production of intricate medical devices is becoming simpler and more affordable thanks to advancements in 3D printing technology. The market is segmented by application, by technology and by end user. Some key players in this market include: Materialise Japan, Roland dg, Siemens Healthineers, GE Healthcare, Stryker and Renishaw.
Japan Healthcare Insurance Market Analysis
The Japan healthcare insurance market is projected to grow from $125.95 Bn in 2022 to $234.85 Bn by 2030, registering a CAGR of 8.1% during the forecast period of 2022 - 2030. The main factors driving the growth would be the ageing population, technological advancements, rising healthcare costs and government initiatives. The market is segmented by component, provider, coverage, by health insurance plans and end-user. Some of the major players include Nippon Life Insurance, Daiichi Life Insurance, Tokio Marine Insurance and Sompo Japan Insurance.
Japan ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis
Japan's Attention Deficit Hyperactivity Disorder (ADHD) therapeutics market is projected to grow from $1.8 Bn in 2022 to $3.4 Bn in 2030 with a CAGR of 8% for the year 2022-30. This market growth is attributed to the rise in ADHD prevalence in Japan and consequently the demand for new drugs and their approvals. The Japan ADHD therapeutics market is segmented by drug, drug type, demographics, and by distribution channel. Some of the leading players in the market include Kouken, Lupin, and Takeda Pharmaceuticals.
Japan Healthcare Claims Management Market Analysis
The Japan healthcare claims management market is projected to grow from $1.66 Bn in 2022 to $9.22 Bn by 2030, registering a CAGR of 12.2% during the forecast period of 2022 - 2030. The main factors driving the growth would be the ageing population, government initiatives, technological advancements and increasing healthcare expenditure. The market is segmented by component, by type, delivery mode and end-user. Some of the major players include NTT Data, iChain, Cognizant, Accenture and Genpact.
Japan Liver Diseases Therapeutics Market Analysis
By 2030, it is anticipated that the Japan Liver Disease Therapeutics market will reach a value of $2.3 Bn from $1.4 Bn in 2022, growing at a CAGR of 6.2% during 2022-2030. Liver Disease Therapeutics in Japan is dominated by domestic pharmaceutical companies such as Aspen Pharmacare Japan, Mayne Pharma, and Phebra. The Liver Disease Therapeutics market in Japan is segmented into different types of disease and different therapy types. Some of the significant factors affecting the Japan Liver Disease Therapeutics market are the growing prevalence of liver diseases and unhealthy and dynamic lifestyles.
Japan Oncology Clinical Trials Market Analysis
Japan's oncology clinical trials market is projected to grow from $0.79 Bn in 2022 to $1.25 Bn by 2030, registering a CAGR of 6% during the forecast period of 2022-30. The market will be driven by a well-established healthcare system, advanced infrastructure, and a high prevalence of cancer. The market is segmented by phase, by study design & by indication. Some of the major players include Novartis International AG, Chugai Pharmaceutical Co., Ltd. & Ono Pharmaceutical Co., Ltd.
Japan Diabetes Drugs Market Analysis
The Japan diabetes drugs market size was valued at $3.84 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 6.6% from 2022 to 2030 and will reach $6.4 Bn in 2030. The market is segmented by drug type, application, and distribution channel. The Japan diabetes drug market will grow because of the Japanese government's initiatives to improve healthcare infrastructure and increase awareness about diabetes management. The key market players are Takeda Pharmaceutical (JPN), Astellas Pharma (JPN), Daiichi Sankyo (JPN), Sumitomo Dainippon (JPN) others.
Japan Connected Healthcare Market Analysis
The Japan-connected healthcare market is projected to grow from $4.13 Bn in 2022 to $31.44 Bn by 2030, registering a CAGR of 28.9% during the forecast period of 2022 - 2030. The main factors driving the growth would be the ageing population, shortage of healthcare workers, technological innovation and government support. The market is segmented by type, function and by application. Some of the major players include Sony, Hitachi, Fujitsu Limited, Apple, Cisco Systems, IBM and GE Healthcare.
Japan Anemia Drugs Market Analysis
Japan's Anemia drugs market was valued at $993 Mn in 2022 and is estimated to expand at a CAGR of 9.40% from 2022-30 and will reach $2038 Mn in 2030. One of the main reasons propelling the growth of this market is the introduction of newer technologies, and the aging population. The market is segmented by type, drug, and distribution channel. Some key players in this market are Pfizer, Astellas Pharma, Takeda Pharmaceutical, Daiichi Sankyo Company, Chugai Pharmaceutical, Otsuka Holdings, Roche, and GSK among others.
Japan Neurology Clinical Trials Market Analysis
The Japan Neurology Clinical Trials market is projected to grow from $325.1 Mn in 2022 to $518.1 Mn by 2030, registering a CAGR of 6% during the forecast period of 2022 - 2030. The market will be driven by the high prevalence of neurological diseases and a robust healthcare system. The market is segmented by phase, by study design & by indication. Some of the major players include Novartis, Pfizer, Eisai Co., Ltd & Daiichi Sankyo.
Japan Infectious Disease Therapeutics Market Analysis
By 2030, it is anticipated that the Japan infectious disease therapeutics market will reach a value of $10.88 Bn from $7.45 Bn in 2022, growing at a CAGR of 4.9% during 2022-2030. Infectious Disease Therapeutics in Japan is dominated by a few domestic pharmaceutical companies such as Astellas Pharma, Daiichi Sankyo and Takeda Pharmaceutical. The Infectious Disease Therapeutics market in Japan is segmented into different therapeutic areas and different diseases type. The major factors affecting the Japanese infectious disease therapeutics market are the increasing disease burden of communicable diseases like TB, hepatitis, and COVID-19 and the amount of healthcare funding for infectious disease treatment in various areas of Japan.
Japan Robotic Surgery Services Market Analysis
The Japan Robotic Surgery Service market size was valued at $267 Mn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 19.8% % from 2022 to 2030 and will reach $1131 Mn in 2030. The robotic surgery service market will grow due to the development of new and improved robotic surgical systems is making these procedures more accessible and affordable, and helping to increase awareness about their benefits among healthcare providers and patients. The market is segmented by product and service type, application type, and end user. Some of the major players are Stryker Corporation, Smith & Nephew, TransEnterix Surgical, Inc., and others
Japan Acne Therapeutics Market Analysis
The Japan acne therapeutics market size was valued at $623 Mn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 7.2% from 2022 to 2030 and will reach $1,087 Mn in 2030. The main factors contributing to this market growth are the rising prevalence of acne and the demand for innovative treatment options in Japan. The market is segmented by treatment, route of administration, age group, and by distribution channel. Otsuka Pharmaceuticals, Torii Pharmaceuticals, and Teva Pharmaceuticals are key competitors in Japan acne therapeutics market.
Japan Home Healthcare Market Analysis
The Japan home healthcare market was valued at $22.4 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 8.43% from 2022 to 2030 and will reach $43.07 Bn in 2030. One of the main reasons propelling the growth of this market is the introduction of newer technologies, The increased prevalence of chronic ailments. The market is segmented by equipment and by services. Some key players in this market are Doctor mate, Medtronic Japan, A&D Company, and Toto.
Japan Cancer Pain Management Market Analysis
Japan's Cancer Pain Management market is projected to grow from $405.27 Mn in 2022 to $636.26 Mn by 2030, registering a CAGR of 5.8% during the forecast period of 2022 - 2030. The main factors driving the growth would be high healthcare expenditure, advanced healthcare infrastructure, an aging population, and government support. The market is segmented by drug type and by disease. Some of the major players include Daiichi Sankyo (JPN), Hisamitsu Pharmaceutical Co (JPN), Mundipharma, Pfizer, and Teva Pharmaceuticals.
Japan Orphan Diseases Drugs Market Analysis
The Japan Orphan Diseases Drugs Market is projected to grow from $9.623 Bn in 2022 to $21.858 Bn by 2030, registering a CAGR of 10.80% during the forecast period of 2022 – 2030. Some of the most common orphan diseases in Japan include hemophilia, Gaucher disease, and Morquio syndrome. Some of the key players in the Japan orphan diseases drugs market are Takeda Pharmaceuticals, Pfizer, Novartis, Sanofi, Roche Holding, Shire, Chugai Pharmaceutical, Eisai, Sumitomo Dainippon Pharma, and Astellas Pharma.
Japan Lung Cancer Drugs Market Analysis
The Japan Lung Cancer Drug Market is projected to grow from $0.594 Bn in 2022 to $1.167 Bn by 2030, registering a CAGR of 8.8% during the forecast period of 2022 - 2030. The Japanese government also plays a significant role in the lung cancer drug market through its national health insurance program, which covers the costs of drugs for patients with lung cancer. There are several Japanese pharmaceutical companies that have a strong presence in the lung cancer drug market in Japan, such as Astellas Pharma, Eisai Co., Ltd., Takeda Pharmaceutical Company Limited, etc.
